Prevention of hepatitis A infections

Guidelines for use of hepatitis A vaccine and immune globulin

N. A. Halsey, P. J. Chesney, M. A. Gerber, D. S. Gromisch, S. Kohl, S. M. Marcy, M. I. Marks, Dennis L Murray, Jr Overall, L. K. Pickering, R. J. Whitley, R. Yogev, G. Peter

Research output: Contribution to journalReview article

43 Citations (Scopus)

Abstract

The licensing of two inactivated hepatitis A vaccines for persons 2 years or older necessitates development of recommendations for pediatric use, as well as a review of the current indications for immune globulin (IG) in hepatitis A prophylaxis. Both vaccines are immunogenic and protective in children and adults. A single dose of vaccine induced antibody in 88% to 96% of subjects by 2 weeks and 97% to 100% by 1 month, and protected against subsequent hepatitis A virus (HAV) disease occurring 21 days after receipt of the dose in a community with endemic hepatitis A infection. However, completion of the full vaccine schedule is recommended to assure high antibody titers and likely long-term protection. The major pediatric indications for vaccine are: (1) travelers to areas with intermediate to high rates of endemic hepatitis A, 12) children living in defined and circumscribed communities with high endemic rates or periodic outbreaks of HAV infection, and (3) patients with chronic liver disease. Immune globulin is recommended for postexposure prophylaxis, as vaccine has not yet been demonstrated to be protective for this purpose. Except for travelers, recommendations for IG use are not changed from those in the current edition of the Red Book, and include contacts of cases in the home, child care centers, and other selected sites.

Original languageEnglish (US)
Pages (from-to)1207-1215
Number of pages9
JournalPediatrics
Volume98
Issue number6
StatePublished - Dec 1 1996

Fingerprint

Hepatitis A Vaccines
Hepatitis A
Immunoglobulins
Vaccines
Guidelines
Hepatitis A virus
Infection
Virus Diseases
Pediatrics
Inactivated Vaccines
Antibodies
Licensure
Home Care Services
Child Care
Disease Outbreaks
Liver Diseases
Appointments and Schedules
Chronic Disease

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Halsey, N. A., Chesney, P. J., Gerber, M. A., Gromisch, D. S., Kohl, S., Marcy, S. M., ... Peter, G. (1996). Prevention of hepatitis A infections: Guidelines for use of hepatitis A vaccine and immune globulin. Pediatrics, 98(6), 1207-1215.

Prevention of hepatitis A infections : Guidelines for use of hepatitis A vaccine and immune globulin. / Halsey, N. A.; Chesney, P. J.; Gerber, M. A.; Gromisch, D. S.; Kohl, S.; Marcy, S. M.; Marks, M. I.; Murray, Dennis L; Overall, Jr; Pickering, L. K.; Whitley, R. J.; Yogev, R.; Peter, G.

In: Pediatrics, Vol. 98, No. 6, 01.12.1996, p. 1207-1215.

Research output: Contribution to journalReview article

Halsey, NA, Chesney, PJ, Gerber, MA, Gromisch, DS, Kohl, S, Marcy, SM, Marks, MI, Murray, DL, Overall, J, Pickering, LK, Whitley, RJ, Yogev, R & Peter, G 1996, 'Prevention of hepatitis A infections: Guidelines for use of hepatitis A vaccine and immune globulin', Pediatrics, vol. 98, no. 6, pp. 1207-1215.
Halsey NA, Chesney PJ, Gerber MA, Gromisch DS, Kohl S, Marcy SM et al. Prevention of hepatitis A infections: Guidelines for use of hepatitis A vaccine and immune globulin. Pediatrics. 1996 Dec 1;98(6):1207-1215.
Halsey, N. A. ; Chesney, P. J. ; Gerber, M. A. ; Gromisch, D. S. ; Kohl, S. ; Marcy, S. M. ; Marks, M. I. ; Murray, Dennis L ; Overall, Jr ; Pickering, L. K. ; Whitley, R. J. ; Yogev, R. ; Peter, G. / Prevention of hepatitis A infections : Guidelines for use of hepatitis A vaccine and immune globulin. In: Pediatrics. 1996 ; Vol. 98, No. 6. pp. 1207-1215.
@article{b2542a6599794da78c10d99ee677810a,
title = "Prevention of hepatitis A infections: Guidelines for use of hepatitis A vaccine and immune globulin",
abstract = "The licensing of two inactivated hepatitis A vaccines for persons 2 years or older necessitates development of recommendations for pediatric use, as well as a review of the current indications for immune globulin (IG) in hepatitis A prophylaxis. Both vaccines are immunogenic and protective in children and adults. A single dose of vaccine induced antibody in 88{\%} to 96{\%} of subjects by 2 weeks and 97{\%} to 100{\%} by 1 month, and protected against subsequent hepatitis A virus (HAV) disease occurring 21 days after receipt of the dose in a community with endemic hepatitis A infection. However, completion of the full vaccine schedule is recommended to assure high antibody titers and likely long-term protection. The major pediatric indications for vaccine are: (1) travelers to areas with intermediate to high rates of endemic hepatitis A, 12) children living in defined and circumscribed communities with high endemic rates or periodic outbreaks of HAV infection, and (3) patients with chronic liver disease. Immune globulin is recommended for postexposure prophylaxis, as vaccine has not yet been demonstrated to be protective for this purpose. Except for travelers, recommendations for IG use are not changed from those in the current edition of the Red Book, and include contacts of cases in the home, child care centers, and other selected sites.",
author = "Halsey, {N. A.} and Chesney, {P. J.} and Gerber, {M. A.} and Gromisch, {D. S.} and S. Kohl and Marcy, {S. M.} and Marks, {M. I.} and Murray, {Dennis L} and Jr Overall and Pickering, {L. K.} and Whitley, {R. J.} and R. Yogev and G. Peter",
year = "1996",
month = "12",
day = "1",
language = "English (US)",
volume = "98",
pages = "1207--1215",
journal = "Pediatrics",
issn = "0031-4005",
publisher = "American Academy of Pediatrics",
number = "6",

}

TY - JOUR

T1 - Prevention of hepatitis A infections

T2 - Guidelines for use of hepatitis A vaccine and immune globulin

AU - Halsey, N. A.

AU - Chesney, P. J.

AU - Gerber, M. A.

AU - Gromisch, D. S.

AU - Kohl, S.

AU - Marcy, S. M.

AU - Marks, M. I.

AU - Murray, Dennis L

AU - Overall, Jr

AU - Pickering, L. K.

AU - Whitley, R. J.

AU - Yogev, R.

AU - Peter, G.

PY - 1996/12/1

Y1 - 1996/12/1

N2 - The licensing of two inactivated hepatitis A vaccines for persons 2 years or older necessitates development of recommendations for pediatric use, as well as a review of the current indications for immune globulin (IG) in hepatitis A prophylaxis. Both vaccines are immunogenic and protective in children and adults. A single dose of vaccine induced antibody in 88% to 96% of subjects by 2 weeks and 97% to 100% by 1 month, and protected against subsequent hepatitis A virus (HAV) disease occurring 21 days after receipt of the dose in a community with endemic hepatitis A infection. However, completion of the full vaccine schedule is recommended to assure high antibody titers and likely long-term protection. The major pediatric indications for vaccine are: (1) travelers to areas with intermediate to high rates of endemic hepatitis A, 12) children living in defined and circumscribed communities with high endemic rates or periodic outbreaks of HAV infection, and (3) patients with chronic liver disease. Immune globulin is recommended for postexposure prophylaxis, as vaccine has not yet been demonstrated to be protective for this purpose. Except for travelers, recommendations for IG use are not changed from those in the current edition of the Red Book, and include contacts of cases in the home, child care centers, and other selected sites.

AB - The licensing of two inactivated hepatitis A vaccines for persons 2 years or older necessitates development of recommendations for pediatric use, as well as a review of the current indications for immune globulin (IG) in hepatitis A prophylaxis. Both vaccines are immunogenic and protective in children and adults. A single dose of vaccine induced antibody in 88% to 96% of subjects by 2 weeks and 97% to 100% by 1 month, and protected against subsequent hepatitis A virus (HAV) disease occurring 21 days after receipt of the dose in a community with endemic hepatitis A infection. However, completion of the full vaccine schedule is recommended to assure high antibody titers and likely long-term protection. The major pediatric indications for vaccine are: (1) travelers to areas with intermediate to high rates of endemic hepatitis A, 12) children living in defined and circumscribed communities with high endemic rates or periodic outbreaks of HAV infection, and (3) patients with chronic liver disease. Immune globulin is recommended for postexposure prophylaxis, as vaccine has not yet been demonstrated to be protective for this purpose. Except for travelers, recommendations for IG use are not changed from those in the current edition of the Red Book, and include contacts of cases in the home, child care centers, and other selected sites.

UR - http://www.scopus.com/inward/record.url?scp=10544221633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10544221633&partnerID=8YFLogxK

M3 - Review article

VL - 98

SP - 1207

EP - 1215

JO - Pediatrics

JF - Pediatrics

SN - 0031-4005

IS - 6

ER -